Header image Header image
HOME | BOARD | | LOCATION MAP | CONTACT US
 
OUR CAMPUS
COLLABORATIVE RESEARCH
LIBRARY
MEDIA CENTRE
DATABASES

 
ISID-PHFI
Research Programme

The Institute for Studies in Industrial Development (ISID) and the Public Health Foundation of India (PHFI) have entered into a MOU for undertaking collaborative research in the areas of pharmaceuticals, medical devices and healthcare sectors, health innovation, R&D and public health and capacity building exercise. The research output of the programme will be disseminated through reports, research papers, mimeographs and short films. The broad components and the specific research studies planned under the programme for the period 2013-14 and 2014-15 are:

  1. Emerging systems of research for health and making of health innovation in the sectors of drugs and pharmaceuticals, medical devices, healthcare delivery and traditional healthcare
  2. PHFI has been requested by the Government of Andhra Pradesh to conduct and evaluation of this scheme. PHFI and ISID will collaborate to undertake an evaluation of this scheme in terms of designing the evaluation and conducting data analysis. The project is expected to be for a two year duration (June 2012 to May 2014).

    1. Innovation making in publicly funded sector of health R&D in India: Experience during the reform period and implications for the future.
    2. Innovation & Commercialisation in the emergent medical technology sector in India.
    3. Studies on the emergence and development of “In-Vitro- diagnostics” industry in India.
    4. Do the clinical trials in India exploit the poor and vulnerable people?

  3. Promotion and regulation of foreign direct investment, public and private investment and its impact on quality of healthcare, access to healthcare services
  4. Under this theme the focus will be on the changing patterns of foreign participation via FDI, Private Equity (PE) and Venture Capital (VC) and the consequences for development of pharmaceutical and healthcare industry. Studies will be undertaken on the proposed changes in the patterns of public financing, promotion of insurance of healthcare, user fees and other related developments. It is also proposed to look at the consequences of proposed introduction of the mechanism of public financing for the promotion of private provisioning of healthcare and its impact on the dimensions of sustainability and equity in public health.

    1. Impact evaluation of health insurance schemes in India.
    2. Investment (FDI) in healthcare sector in India.
    3. Estimating tax incidence of tobacco products in India: An empirical analysis.
    4. Health insurance and incidence of service benefits: Empirical evidences from select Indian states.
    5. Do market supply chain and public procurement of medicine leads to better access to medicine in India: A comparative analysis.
    6. Impact of health policy changes on equity and fairness of the health care financing in India.

  5. Post-TRIPS Intellectual property developments, pharmaceutical industry and access to essential medicines in India
  6. In this theme our focus will be on the impact of implementation of the changes in patenting behavior of domestic private sector, foreign companies and CSIR after the implementation of amended Patent Law of 2005. First of all, patented medicines need to be socially, economically and technically valued in terms of what can be characterized as new drug products versus products referred to as follow-on, incremental, line extension, me too, and supplemental inventions in respect of different kinds of therapeutic areas. Second, we need to identify the strength of barriers being erected by the patent holders in respect of different types of follow-on innovations and assess the ability of new and emerging patent owners to forestall generic entry on older blockbuster drugs under the Indian conditions by various routes including by practicing strategic use of “defensive patenting strategies”, “voluntary licensing practices” and “patent linkage with other anti-competitive practices”.

    1. Assessment of patents, industrial capability and policy instruments to improve access to patented knowledge for diagnostics, drugs and vaccines for some Type III diseases in the Indian context.
    2. Post-TRIPS patenting behaviour of the domestic and foreign pharmaceutical firms and CSIR.

  7. Emerging regime of promotion and regulation of trade and investment in health services under WTO
  8. In this component we will have to consider a number of factors while assessing implications of the emerging regime of promotion and regulation of trade and investment in health services. The net impact of trade depends on the specifics of a country’s national health care system, the regulatory environment and government policies. In the proposed WTO Agreement each supply mode has associated benefits and problems. We will examine the following issues: What are the costs and benefits of each mode to India? What should be the roadmap on health care liberalization for India? What effect might liberalization have on national health policy?

    1. Emerging regime of promotion and regulation of trade and investment in health services under WTO.

  9. Human resources for healthcare and research and innovation in health, foreign participation in medical education
  10. Under this theme emerging patterns of public and private investment in the systems of education and research in 1) medicine, 2) chemistry, 3) biology, 4) pharmacology & pharmacy, 5) bioprocessing, 6) health biotechnology, 7) medical electronics, 8) health informatics and other related fields and its impact of the changing patterns of investment in education and research organizations on the aspects of quality and outcomes in respect of development of healthcare services, contribution to health innovation and industrial development will be taken up.

    1. Quality of human resources for health in India: Evidences from a field study.
    2. Foreign providers in medical education services in India: Mapping the challenges and opportunities.

  11. Institutional and policy framework for the practice of efficiency in the delivery of healthcare, innovation making and industrial development
  12. As the post-reform institutional changes have influenced in a big way the processes of “establishment of vision and strategy”, “steering and coordination”, “regulation”, “demand creation” and “learning” in respect of the development of pharmaceutical value chains, systems of delivery of healthcare, production of diagnostics and medical devices, the impact of these changes on the dimensions of access and innovation making with regard to the development and delivery of health services / products. Major strategic shifts have taken place along the value chain in the case of both pharmaceutical industry and health sector. Strategic alliances, collaborations and PPPs, harmonization of regulation and procurement and many other related changes are impacting on the realization of goals of public health. Studies are required to be undertaken on the aspects of access to healthcare and upgrading of capabilities for innovation in health sector, development of public services and health related industries. In this component of research our focus will be on the issue of how the above described changes in the institutional environment have been finally responded by the actors directly involved in the delivery of healthcare, production of pharmaceuticals, diagnostics and medical devices in terms of their strategy and performance.

    1. Translating innovation into industrial policy: Role of government, industry, public service systems and social movements.

    The programme as described above would be taken up with the help of existing faculty, engaging consultants, professionals, research analysts and associates. Besides these we need to acquire and create databases, development of library and documentation, create network of research institutions and scholars and promotion of communication etc. and use of the results of research in order to make an impact on policy making and advocacy.

Working Paper Series

Capacity Building-cum-Workshop
Pharmaceutical Policies in India:
Balancing Industrial and Public Health Interests

03-05 March 2014

Two-day National Conference
Pharmaceutical Policies in India:
Balancing Industrial and Public Health Interests

06-07 March 2014

Internal Seminars / Presentations

  • Shailender Kumar Hooda, "Changing Pattern of Public Expenditure on Health in India: Issues and Challenges", 21 May 2013
  • Pritam Datta, PHFI, "Medical Devices Manufacturing Industry in India: Market Structure, Import Intensity and Regulatory Mechanisms", 21 May 2013
  • Shailender Kumar Hooda, "Access to and Financing of Healthcare through Health Insurance Intervention in India", 11 November 2013
  • Pradeep Kumar Choudhury, "Explaining the Role of Parental Education in the Regional Variation of Infant Mortality in India", 18 November 2013
  • Jinusha Panigrahi, "Foreign Providers in Medical Education Services in India: Mapping the Challenges and Opportunities", 29 November 2013
  • Swadhin Mondal, "Health Policy Changes and Their Impact on Equity of Financing Among Households in India", January 03, 2014
  • Nidhi Singh, "Biomedical Innovations for Resource Poor Settings in India: Case of in Invitro Diagnostics", March 31, 2014
  • Shreyas Reddy, Evolution of Technological Systems in Medical Electronics: Providing a Context for Policy", March 31, 2014
  • Shailender Kumar Hooda, Catastrophic Health Payments and Household Well-being: How Does Effective State Intervention Matter?" March 31, 2014 
 
Last updated Tuesday, April 1, 2014 11:54 AM

         
roller